HUTCHMED and AstraZeneca completed randomization of 338 patients in SAFFRON, a global, open-label Phase III comparing all-oral savolitinib plus osimertinib against platinum doublet chemotherapy in EGFR-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC after progression on osimertinib. The last patient was randomized on October 31, 2025, across more than 230 sites in 29 countries. Progression-free survival by blinded independent central review is the primary endpoint, with topline readout targeted for the first half of 2026.
The core development is the transition of a China-first strategy into a global registration bid. The combination already secured approval in China in June 2025 on SACHI, a randomized Phase III in MET-amplified disease post-EGFR TKI. SAFFRON broadens the biomarker to include MET overexpression and/or amplification and received FDA Fast Track designation. The program is anchored by earlier signals from TATTON and the single-arm Phase II SAVANNAH, which showed meaningful responses in MET-driven resistance after osimertinib. SANOVO complements it in the first-line setting, where enrollment was completed in August 2025.
Strategically, the sponsors are aiming to keep post-osimertinib patients on a targeted, chemotherapy-sparing pathway built around AstraZeneca’s EGFR franchise. The all-oral regimen challenges the entrenched default to platinum doublet and competes with an increasingly crowded resistance landscape that includes bispecific antibody combinations and emerging ADCs. Broadening eligibility to MET overexpression expands the reachable population but introduces diagnostic ambiguity that can dilute effect size and complicate regulatory alignment on companion diagnostics. The site footprint underscores that tension: screening across 230-plus centers to randomize 338 patients reflects the variability and operational friction of post-progression MET testing, where prevalence estimates swing widely by assay and cutoff.
For sites, SAFFRON’s model hinges on rapid re-biopsy or validated plasma testing at progression, standardization of MET assessment, and short lab turnaround times to prevent attrition. That pushes imaging schedules, pathology workflows, and consent-to-randomization intervals, with central review adding a layer of coordination. CROs and labs will feel pressure to harmonize IHC, ISH, and NGS approaches for MET while keeping screen failure rates manageable. Regulators are likely to interrogate assay selection and subgroup consistency between MET-amplified and MET-overexpressed cohorts, and whether any approval should be tethered to a specific test. For patients and prescribers, a tolerable oral doublet that avoids infusions and steroids would be operationally attractive. Still, safety liabilities typical of dual TKIs—edema, gastrointestinal events, and ILD signals—will be watched closely given chronic exposure.
The immediate watchlist focuses on the magnitude of PFS benefit relative to chemo, intracranial control, and the concordance of effect across MET-overexpression and amplification strata. OS will matter in regions where chemo remains a high bar and as competitors move earlier with antibody and ADC combinations. The sponsors also have to lock a coherent diagnostic path, likely a companion or coordinated IVD strategy, to avoid post-approval friction on coverage and test availability. If SAFFRON reads out positively, filings could move in 2026. Still, shifting standards—such as broader uptake of chemo-added osimertinib or bispecific regimens after progression—could challenge the comparators’ relevance and label scope. SANOVO’s first-line data will shape how far the combo can stretch up the treatment cascade. Still, operationally, the near-term determinant is whether SAFFRON demonstrates a clear, biomarker-driven, oral alternative that sites can execute at scale without prohibitive diagnostic drag.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
